IN2012DN00954A - - Google Patents

Info

Publication number
IN2012DN00954A
IN2012DN00954A IN954DEN2012A IN2012DN00954A IN 2012DN00954 A IN2012DN00954 A IN 2012DN00954A IN 954DEN2012 A IN954DEN2012 A IN 954DEN2012A IN 2012DN00954 A IN2012DN00954 A IN 2012DN00954A
Authority
IN
India
Prior art keywords
compound
methyl
salt
tablet
content
Prior art date
Application number
Other languages
English (en)
Inventor
Murakawa Yusuke
Okabe Takayuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00954(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of IN2012DN00954A publication Critical patent/IN2012DN00954A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN954DEN2012 2009-07-28 2010-07-27 IN2012DN00954A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009175695 2009-07-28
PCT/JP2010/062568 WO2011013639A1 (ja) 2009-07-28 2010-07-27 錠剤

Publications (1)

Publication Number Publication Date
IN2012DN00954A true IN2012DN00954A (zh) 2015-04-10

Family

ID=43529294

Family Applications (1)

Application Number Title Priority Date Filing Date
IN954DEN2012 IN2012DN00954A (zh) 2009-07-28 2010-07-27

Country Status (23)

Country Link
US (1) US20120129878A1 (zh)
EP (1) EP2460523B1 (zh)
JP (1) JP5732394B2 (zh)
KR (1) KR20120039046A (zh)
CN (1) CN102548556A (zh)
AU (1) AU2010279171A1 (zh)
BR (1) BR112012001959A2 (zh)
CA (1) CA2769177A1 (zh)
CL (1) CL2012000182A1 (zh)
CO (1) CO6612226A2 (zh)
CR (1) CR20120061A (zh)
EA (1) EA201270204A1 (zh)
EC (1) ECSP12011699A (zh)
IL (1) IL217560A0 (zh)
IN (1) IN2012DN00954A (zh)
MA (1) MA33539B1 (zh)
MX (1) MX2012001284A (zh)
PE (1) PE20120919A1 (zh)
SG (1) SG178062A1 (zh)
TN (1) TN2012000031A1 (zh)
TW (1) TW201106991A (zh)
WO (1) WO2011013639A1 (zh)
ZA (1) ZA201200761B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
JP6122879B2 (ja) 2012-06-05 2017-04-26 武田薬品工業株式会社 固形製剤
CN103768071B (zh) * 2012-10-23 2016-08-17 中国医药工业研究总院 一种治疗糖尿病的口服制剂
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN105078974A (zh) * 2014-05-23 2015-11-25 深圳信立泰药业股份有限公司 一种阿利沙坦酯固体分散体及药物组合物
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
CN105596341B (zh) * 2016-03-14 2018-08-10 石家庄四药有限公司 一种琥珀酸曲格列汀固体制剂及制备方法
WO2017195796A1 (ja) 2016-05-10 2017-11-16 日本臓器製薬株式会社 アセトアミノフェン製剤の製造方法
CN114122219A (zh) * 2020-08-28 2022-03-01 群创光电股份有限公司 发光单元
CN116763752B (zh) * 2023-08-24 2023-11-17 北京福元医药股份有限公司 一种阿卡波糖片剂及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JP2711528B2 (ja) * 1995-12-20 1998-02-10 大洋薬品工業株式会社 ロキソプロフェン製剤
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2002006234A1 (fr) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Derives de sulfonate, procede de production et utilisation de ces derives
TW200416029A (en) 2002-11-01 2004-09-01 Takeda Chemical Industries Ltd Agent for preventing or treating neuropathy
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
WO2005030740A1 (ja) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
BRPI0418148A (pt) 2003-12-25 2007-04-17 Takeda Pharmaceutical composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
NZ549716A (en) 2004-03-15 2010-04-30 Takeda Pharmaceutical Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JP4919252B2 (ja) * 2004-08-05 2012-04-18 株式会社明治 顆粒状製剤及びその製造方法
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
ES2434072T3 (es) * 2005-06-09 2013-12-13 Norgine Bv Preparación sólida de 2-hexadeciloxi-6-metil-4H-3,1-benzoxacin-4-ona
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2007211005A (ja) * 2006-01-16 2007-08-23 Ono Pharmaceut Co Ltd 固形製剤用組成物および固形製剤
RS52307B (en) 2006-06-27 2012-12-31 Takeda Pharmaceutical Company Limited CONDENSED CYCLIC UNITS
KR20090088854A (ko) 2006-09-13 2009-08-20 다케다 야쿠힌 고교 가부시키가이샤 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
KR101444486B1 (ko) 2006-10-19 2014-09-24 다케다 야쿠힌 고교 가부시키가이샤 인돌 화합물
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
PE20081734A1 (es) * 2007-02-01 2009-01-19 Takeda Pharmaceutical Comprimido que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y celulosa microcristalina
EA200970746A1 (ru) 2007-02-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Конденсированные циклические соединения в качестве частичных агонистов ppar-гамма
US7994183B2 (en) * 2007-03-13 2011-08-09 Takeda Pharmaceutical Company Limited Solid preparation comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
US8400391B2 (en) 2008-01-10 2013-03-19 Honeywell International Inc. Method and system for improving dimming performance in a field sequential color display device

Also Published As

Publication number Publication date
CN102548556A (zh) 2012-07-04
JPWO2011013639A1 (ja) 2013-01-07
CA2769177A1 (en) 2011-02-03
CR20120061A (es) 2012-03-06
EP2460523A1 (en) 2012-06-06
CO6612226A2 (es) 2013-02-01
EA201270204A1 (ru) 2012-08-30
WO2011013639A1 (ja) 2011-02-03
AU2010279171A1 (en) 2012-03-01
TN2012000031A1 (en) 2013-09-19
JP5732394B2 (ja) 2015-06-10
BR112012001959A2 (pt) 2016-03-15
CL2012000182A1 (es) 2012-10-12
EP2460523B1 (en) 2017-01-04
MX2012001284A (es) 2012-03-26
ECSP12011699A (es) 2012-03-30
SG178062A1 (en) 2012-03-29
US20120129878A1 (en) 2012-05-24
EP2460523A4 (en) 2014-02-26
TW201106991A (en) 2011-03-01
IL217560A0 (en) 2012-02-29
MA33539B1 (fr) 2012-08-01
ZA201200761B (en) 2013-05-29
KR20120039046A (ko) 2012-04-24
PE20120919A1 (es) 2012-08-13

Similar Documents

Publication Publication Date Title
IN2012DN00954A (zh)
TW200612958A (en) Substituted imidazole derivatives
TW200801000A (en) Spiroindolinone derivatives
MX2009009703A (es) Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo.
MX2007004699A (es) Derivados de indol y bencimidazol.
MX2010004576A (es) Derivados de pirimidina novedosos.
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
JO2761B1 (en) Derivatives of alcohols 1-phenyl-2-pyridinealkyl as inhibitors
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
TN2010000044A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
MY151295A (en) Pyrimidyl indoline compound
MX2011012523A (es) Esteres cetalicos de anhidropentitoles y usos de los mismos.
HRP20080493T3 (en) Substituted quinoline derivatives as mitotic kinesin inhibitors
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
UA105229C2 (uk) Фармацевтичний склад
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
MY161461A (en) Akt and p70 s6 kinase inhibitors
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
MX2009006266A (es) Procedimientos de preparacion de 3-(4-(2,4-difluorobenciloxi)-3-br omo-6-metil-2-oxopiridin-1 (2h)-il)-n,4-dimetilbenzamida.
MY153733A (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
TW200531693A (en) Prolonged-release diuretic compositions